I am interested in investigating the molecular mechanisms and identifying therapeutic targets of neurodegenerative diseases.
- 2019 – present: Research fellow, Autifony Therapeutics collaborative research with Edinburgh Dementia Research Institute
- 2015 – 2019: PhD, Translational Neuroscience, University of Aberdeen, funded by Alzheimer’s Society
- 2012 – 2015: Bsc Hons, Biomedical Science, Lancaster University
The aberrant expression of the voltage-gated potassium channel subunit Kv3.4 leads to altered synaptic activity in neurodegenerative diseases. I aim to characterise Kv3.4 abundance in human post-mortem brains affected with Alzheimer’s disease, Parkinson’s disease and ALS, respectively.
In parallel with this, I utilise stereotactic injection techniques coupled with advanced imaging systems such as array tomography to investigate the impact of Kv3.4 abundance on dendritic spine density in Alzheimer’s mouse models. Since dendritic spine loss is one of the earliest features in neurodegenerative diseases and correlates well with disease progression, the ability to prevent dendritic spine loss by modulating Kv3.4 level would represent a novel therapeutic target for the disease.
Yeap, J.M., Crouch, B., Riedel, G. & Platt, B. 2020. Sequential habituation to space, object and stranger is differentially modulated by glutamatergic, cholinergic and dopaminergic transmission. Behav Pharmacol. 31(7):652-70. DOI: 10.1097/FBP.0000000000000573
Crouch, B., Yeap, J.M., Pais, B., Riedel, G. & Platt, B. 2018. Of mice and motion: Behavioural-EEG phenotyping of Alzheimer’s disease mouse models. J Neurosci Methods. S0165-0270(18):30206-1. DOI: 10.1016/j.jneumeth.2018.06.028
Plucinska, K., Crouch, B., Yeap, J.M., Stoppelkamp, S., Riedel, G. & Platt, B. 2018. Histological and behavioural phenotypes of a novel mutated APP knock-in mouse. J Alzheimers Dis. 65(1):165-180. DOI: 10.3233/JAD-180336